Biontech Se Sponsored Adr (BNTX)
NASDAQ:BNTX
Want to see BNTX full AI Analyst Report?
Top Page
BioNTech SE
(NASDAQ:BNTX)
Select Model
Select Model
Rating:55Neutral
Price Target:
$96.00
▼(-6.72% Downside)
Action:Reiterated
Date:05/09/26
The score reflects a strong financial backstop (very low leverage and substantial liquidity, with improved recent free cash flow) but a weak near-term earnings profile (losses and volatile revenues). Technical indicators are bearish with the stock below key moving averages and negative MACD. The latest earnings call supports the medium-term pipeline narrative, but 2026 guidance points to lower revenues and higher spend, keeping the overall score in the mid-range.
Positive Factors
Conservative balance sheet
Very low leverage and substantial equity create durable financial optionality: BioNTech can fund multi-year, high-cost oncology development, absorb trial setbacks, and pursue strategic deals or manufacturing consolidation without immediate financing stress, supporting execution over the next 2–6 months and beyond.
Negative Factors
2026 revenue decline guidance
A guided material revenue drop reflects post-pandemic normalization and reduced COVID franchise contribution. That lowers near-term top-line cover for rising R&D and SG&A, forcing reliance on pipeline catalysts and cash reserves to bridge the commercialization gap over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and substantial equity create durable financial optionality: BioNTech can fund multi-year, high-cost oncology development, absorb trial setbacks, and pursue strategic deals or manufacturing consolidation without immediate financing stress, supporting execution over the next 2–6 months and beyond.
Read all positive factors
BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.47B
Dividend YieldN/A
Average Volume (3M)920.38K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth10.01%
EPS Growth-71.78%
CountryUS
Employees6,772
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.09
Shares Outstanding252,884,260
10 Day Avg. Volume942,182
30 Day Avg. Volume920,379
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda-12.07
Forecast
1Y Price Target
$133.75Price Target Upside29.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.57
Revenue Forecast (FY)$2.15B
BioNTech SE Business Overview & Revenue Model
Company Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance mela...
How the Company Makes Money
BioNTech makes money primarily by commercializing products and by partnering with larger pharmaceutical companies to develop, manufacture, and distribute its therapeutics and vaccines. A major revenue driver has been its collaboration with Pfizer ...
BioNTech SE Earnings Call Summary
Earnings Call Date:Mar 10, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
Overall the call presented a constructive picture: BioNTech outperformed its raised 2025 guidance, preserved a very strong cash position (EUR 17.2 billion), advanced a broad late-stage oncology pipeline with multiple planned readouts in 2026–2030, and executed strategic deals to derisk programs. Offsetting this, management guided materially lower revenues for 2026 (EUR 2.0–2.3bn vs EUR 2.9bn in 2025), highlighted near-term increases in R&D and SG&A to support oncology launches, reported an adjusted net loss (EUR 117m) and disclosed a trial discontinuation in one indication. The founders' planned transition to a new company introduces execution uncertainty but is framed as an orderly process through end-2026. On balance, the positive operational progress, portfolio de-risking and very strong liquidity outweigh the near-term revenue headwinds and costs.Positive Updates
COVID Vaccine Leadership and Market Share
Launched a variant-adapted COVID vaccine with Pfizer; product distributed in over 180 countries and holds more than 50% market share in major markets. Management describes COMIRNATY as a cash-generative franchise with favorable economics under the Pfizer collaboration.
Negative Updates
Projected 2026 Revenue Decline
2026 revenue guidance of EUR 2.0–2.3 billion implies a decline versus 2025 (EUR 2.9 billion) of approximately 20.7% to 31.0%, driven primarily by expected lower COVID-19 vaccine revenues in the U.S. and Europe and the seasonal normalization of demand.
Read all updates
Q4-2025 Updates
Positive
Negative
COVID Vaccine Leadership and Market Share
Launched a variant-adapted COVID vaccine with Pfizer; product distributed in over 180 countries and holds more than 50% market share in major markets. Management describes COMIRNATY as a cash-generative franchise with favorable economics under the Pfizer collaboration.
Read all positive updates
Company Guidance
The company provided adjusted (non‑IFRS) 2026 guidance calling for total revenues of EUR 2.0–2.3 billion, with the same amount and quarterly timing from the BMS collaboration (including a EUR 613 million recognition in the third quarter) but lower COMIRNATY/COVID‑19 vaccine revenues versus 2025; it expects similar pandemic‑preparedness and services revenues but no one‑time Pfizer opt‑out proceeds. Adjusted operating spend is guided to R&D EUR 2.2–2.5 billion and SG&A EUR 700–800 million as BioNTech increases late‑stage oncology investment while reducing non‑priority R&D; 2025 results were EUR 2.9 billion revenue, ~EUR 2.1 billion R&D, an adjusted non‑IFRS net loss of EUR 117 million, and EUR 17.2 billion cash, cash equivalents and securities. Management emphasized guidance and reporting will be on an adjusted basis (excluding legal, impairments, restructuring, bargain purchase and divestiture items), noted COVID revenue seasonality (last four months drive the year) and reiterated operational priorities tied to multiple late‑stage readouts and portfolio de‑risking.BioNTech SE Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
86
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.80B | 2.76B | 2.75B | 3.82B | 17.31B | 18.98B |
| Gross Profit | 2.05B | 2.14B | 2.21B | 3.22B | 14.32B | 16.07B |
| EBITDA | -815.04M | -256.17M | -367.10M | 1.38B | 13.10B | 15.00B |
| Net Income | -1.26B | -1.09B | -665.30M | 930.30M | 9.43B | 10.29B |
Balance Sheet | ||||||
| Total Assets | 21.10B | 21.98B | 22.53B | 23.01B | 23.28B | 15.83B |
| Cash, Cash Equivalents and Short-Term Investments | 14.65B | 14.83B | 16.78B | 16.55B | 14.06B | 2.07B |
| Total Debt | 303.12M | 267.29M | 254.20M | 219.10M | 212.20M | 301.50M |
| Total Liabilities | 2.38B | 2.76B | 3.12B | 2.76B | 3.22B | 3.94B |
| Stockholders Equity | 18.72B | 19.22B | 19.41B | 20.25B | 20.06B | 11.89B |
Cash Flow | ||||||
| Free Cash Flow | 1.26B | 269.81M | -244.60M | 4.67B | 13.21B | 735.70M |
| Operating Cash Flow | 857.99M | 438.00M | 207.70M | 5.37B | 13.58B | 889.70M |
| Investing Cash Flow | -955.08M | -2.37B | -2.08B | -6.95B | -35.30M | -566.10M |
| Financing Cash Flow | -16.12M | -50.81M | -45.90M | -778.60M | -1.42B | 94.20M |
BioNTech SE Technical Analysis
Negative
102.92
Price Trends
94.39
Negative
100.42
Negative
101.51
Negative
Market Momentum
-2.45
Positive
32.78
Neutral
7.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 102.92 is above the 20-day moving average (MA) of 97.05, above the 50-day MA of 94.39, and above the 200-day MA of 101.51, indicating a bearish trend. The MACD of -2.45 indicates Positive momentum. The RSI at 32.78 is Neutral, neither overbought nor oversold. The STOCH value of 7.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $19.02B | 15.46 | 29.31% | ― | 21.48% | 1853.63% | |
79 Outperform | $24.07B | 23.46 | 19.24% | ― | 5.87% | 8.18% | |
63 Neutral | $15.67B | 77.40 | 20.51% | ― | 21.02% | -24.83% | |
56 Neutral | $20.43B | -14.22 | -18.32% | ― | -86.36% | -751.06% | |
55 Neutral | $22.47B | -8.99 | -6.67% | ― | 10.01% | -71.78% | |
53 Neutral | $19.09B | -3.74 | -36.73% | ― | -29.97% | 6.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BNTX
BioNTech SE
87.79
-13.93
-13.69%
INCY
Incyte
95.60
30.30
46.40%
UTHR
United Therapeutics
566.80
257.23
83.09%
GMAB
Genmab
25.68
5.35
26.32%
MRNA
Moderna
45.72
17.73
63.34%
ROIV
Roivant Sciences
28.21
17.17
155.53%
BioNTech SE Corporate Events
BioNTech Launches $1 Billion ADS Buyback to Support Long-Term Growth Strategy
May 7, 2026
On May 7, 2026, BioNTech SE announced it had authorized a new share repurchase program for up to $1.0 billion of its American Depositary Shares, with purchases allowed through May 6, 2027 and funded from existing cash resources. The buyback is int...
BioNTech Posts Wider Q1 Loss as It Doubles Down on Oncology and Plans $1 Billion Buyback
May 5, 2026
On May 5, 2026, BioNTech reported first-quarter 2026 revenues of €118.1 million, down from €182.8 million a year earlier, reflecting lower COVID-19 vaccine sales and resulting in a net loss of €531.9 million. The company reaffirm...
BioNTech Posts Wider Q1 2026 Operating Loss as R&D Spend Weighs on Results
May 5, 2026
On May 5, 2026, BioNTech SE filed a Form 6-K with U.S. regulators reporting unaudited financial results for the quarter ended March 31, 2026 and providing a development update. The company posted first-quarter 2026 revenues of €118.1 million...
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer
Apr 13, 2026
On April 11, 2026, BioNTech SE reported positive primary analysis results from a Phase 2 cohort of its HER2-targeted antibody-drug conjugate trastuzumab pamirtecan in patients with advanced, HER2-expressing recurrent endometrial cancer who had pro...
BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
Apr 2, 2026
BioNTech SE disclosed in an April 2, 2026 Form 6-K that it has convened its 2026 Annual General Meeting for May 15, 2026, to be held virtually without physical shareholder attendance, with participation and voting to occur via an online Investor P...
BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
Mar 24, 2026
BioNTech SE, a leading immunotherapy developer, is expanding its late-stage lung cancer pipeline with a mix of immunomodulators, antibody-drug conjugates and mRNA-based cancer therapies targeting multiple lung cancer subtypes. The company is runni...
BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline
Mar 10, 2026
BioNTech reported on March 10, 2026, that its 2025 revenues rose slightly to €2.87 billion, but it swung to a full-year IFRS net loss of €1.14 billion, or €4.70 per diluted share, mainly due to declining COVID-19 vaccine demand a...
BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline
Mar 10, 2026
On March 10, 2026, BioNTech announced that co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company dedicated to next-generation mRNA innovations, with a management transition targeted by the end of 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.